Form 4: Outlook Therapeutics Director Haddadin Acquires Additional Shares

Director Yezan Munther Haddadin purchased 1,881.7112 shares of Outlook Therapeutics at a weighted average price of $11.82 per share on March 28, 2024.

Summary

• On March 28, 2024, Yezan Munther Haddadin, a director of Outlook Therapeutics, Inc., acquired 1,881.7112 shares of common stock.
• The shares were purchased at a weighted average price of $11.82 per share, with individual transactions ranging from $11.78 to $11.8249.
• Following the transaction, Haddadin directly owns 5,048.7112 shares of Outlook Therapeutics.
• The reported share amounts reflect a 1-for-20 reverse stock split that Outlook Therapeutics implemented on March 13, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director purchasing shares suggests confidence, but the amount is not substantial enough to significantly alter sentiment.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into a company's prospects. Purchases by directors are often viewed more favorably than sales.

Key Dates